Phase III Study of KW-2246 (A Double Blind Study of KW-2246 Compared to Placebo for Breakthrough Pain Episodes in Cancer Patients)

Trial Profile

Phase III Study of KW-2246 (A Double Blind Study of KW-2246 Compared to Placebo for Breakthrough Pain Episodes in Cancer Patients)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Acute pain; Cancer pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 12 Dec 2013 Manufacturing and marketing approval of Abstral in Japan was received on 20 September 2013, ahead of expectations, and the launch has commenced, according to an Orexo media release.
    • 11 Dec 2013 Abstral was launched in Japan, according to a Kyowa Hakko Kirin media release.
    • 24 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top